Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report

BACKGROUND: Dabigatran is a direct thrombin inhibitor with a favorable effectiveness and safety profile when compared to vitamin K antagonists, both in randomized trials and real world registries of atrial fibrillation patients. Yet, physicians’ fear of high bleeding risk scenarios in daily clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Tralhão, António, Aguiar, Carlos, Ferreira, Jorge, Rebocho, Maria José, Santos, Emília, Martins, Dinis, Neves, José Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583973/
https://www.ncbi.nlm.nih.gov/pubmed/28878572
http://dx.doi.org/10.1186/s12959-017-0147-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583973/
https://www.ncbi.nlm.nih.gov/pubmed/28878572
http://dx.doi.org/10.1186/s12959-017-0147-z

Ejemplares similares